Phase I Interim Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)

S Kumar,Ravi Vij,Jonathan L. Kaufman,Joseph R. Mikhael,T. Facon,P. Moreau,Martine Amiot,Stefanie Alzate,Lura Morris,Jeremy A. Ross,Martin Dunbar,Ming Zhu,Suresh Agarwal,Joel D. Leverson,Sari H. Enschede,Rod A. Humerickhouse,Cyrille Touzeau

Phase I Interim Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)

2015

S Kumar
Ravi Vij
Jonathan L. Kaufman
Joseph R. Mikhael
T. Facon
P. Moreau
Martine Amiot
Stefanie Alzate
Lura Morris
Jeremy A. Ross
Martin Dunbar
Ming Zhu
Suresh Agarwal
Joel D. Leverson
Sari H. Enschede
Rod A. Humerickhouse
Cyrille Touzeau

8576 Background: The anti-apoptotic protein BCL-2 has been implicated in mediating the survival of MM cells. Venetoclax (VEN) is a potent, selective, orally bioavailable small-molecule BCL-2 inhibi...

Keywords:

Immunology
Interim
Cancer research
Multiple myeloma
Medicine
Venetoclax
relapsed refractory
Internal medicine
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations